Designed to highlight the incredible innovation taking place outside the walls of traditional pharmaceutical companies, the Beacon Pharmaceutical Incubator will be an intricate part of the Center for Life Sciences & Research in New York City. We plan to initially bring in 50 carefully curated companies focusing on therapeutics, so as to help these smaller players in the industry overcome R&D and financing bottlenecks.
'Right-To-Try' bill for experimental drugs. Beacon Capital is currently in confidential conversations with two prestigious academic institutions and hospitals. The firm had the foresight to implement a strategy impending the approval of the bill. Various join ventures to standardizing a method for offering these compassionate/ experimental treatments. Funding the development of a global database linking pharmaceutical companies and drugs to patients.
Funding seed-stage investments in Life Science startups. Our platform has created a model to finance companies showing great potential for discovery and innovation. Beacon Incubator hopes to fund 20 companies yearly.
Beacon Pharmaceutical Incubator will be an intricate part of the Center for Life Sciences & Research. Exploiting the proximity to New York City. We plan to bring in initially 50 carefully curated companies focusing on therapeutics. $1 Billion market potential and up. These companies will move their HQ in NY State. Working with the New York State program to bring Biotech back to the city a $1 billion initiative
RIGHT TO TRY
SEED FINANCING
INCUBATOR
BEACON PHARMA INVESTMENT FUND
OUR STRATEGIES
Beacon Pharma invests across a global landscape on healthcare related IP, from seed-stage venture capital to publicly-traded companies. Investments are made in one of two approaches: public equity, and private equity:
Funding seed-stage investments in Life Science. Our incubator platform has created a model to finance companies showing great potential for discovery and innovation in health care and biotechnology. Beacon Pharma Incubator will start with 50 companies, and hopes to fund 20 companies yearly while providing them with access to its resources and networks.
​
PUBLIC EQUITY
Beacon Pharma’s public equity fund is back by Beacon Capital. We invest across all types of publicly-traded companies, from therapeutics to medical devices globally.
​
PRIVATE EQUITY
Beacon Pharma’s private equity strategy is comprehensive and nibble, investing from start-ups through, seed convertible debt, and growth equity. We aim to stand beside our portfolio companies, by providing much more than access to capital. We are committed to looking at every befitting transaction no matter what the geographic location may be
Initiatives
BEACON INCUBATOR
Beacon Pharmaceutical Incubator will be an intricate part of the Center for Life Sciences & Research. Exploiting the proximity to New York City. We plan to bring in initially 50 carefully curated companies focusing on therapeutics. $1 Billion market potential and up. These companies will move their HQ in NY State. Working with the New York State program to bring Biotech back to the city a $1 billion initiative. See Link
The incubator will hold minority equity positions in most incubated companies; while providing a vibrant working space as well as access to well designed labs, and manufacturing capabilities. There are currently six incubators in the region that provide office and limited lab space. As the companies graduate from the pre-clinical phase Beacon Pharma will provide them with the additional services and tool needed. Beacon Pharma Incubator will continue to support these businesses for all their needs beyond office and lad space to ensure that they continue to thrive in the State of NY.
